Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years
Adjuvantierter rekombinanter Zoster-Impfstoff ist wirksam gegen Herpes zoster ophthalmicus und ist bei Erwachsenen ab 50 Jahren mit geringerem Risiko für akuten Myokardinfarkt und Schlaganfall assoziiert
Clinical Infectious Diseases · 24.12.2025 · 81 (5) · e441-e445
DOI: 10.1093/cid/ciaf440 ↗Auf einen Blick
Bei Erwachsenen ab 50 Jahren war 2-mal RZV mit geringerem Risiko für HZO, hospitalisierten AMI und hospitalisierten Schlaganfall assoziiert. Die HZO-Wirksamkeit betrug 72,9 %.
Fragestellung
War 2-mal RZV bei Erwachsenen ab 50 Jahren mit geringerem Risiko für HZO, hospitalisierten AMI und hospitalisierten Schlaganfall assoziiert?
Methode
Matched-Kohortenanalyse bei Erwachsenen ab 50 Jahren bei Kaiser Permanente Southern California; 2 RZV-Dosen im Abstand von 4 Wochen–6 Monaten; Cox-Regression mit aHR und 95 %-KI.
Ergebnisse
Vergleich RZV-geimpft vs. ungeimpft: HZO aHR 0,271 (95 %-KI 0,222–0,330); hospitalisierter AMI aHR 0,720 (0,588–0,881); hospitalisierter Schlaganfall aHR 0,575 (0,533–0,619).
Schlussfolgerung der Autor:innen
Bei Erwachsenen ab 50 Jahren waren 2 RZV-Dosen mit geringerem Risiko für HZO, AMI und Schlaganfall assoziiert.
Kernaussagen
- HZO aHR 0,271 (95 %-KI 0,222–0,330)
- Hospitalisierter AMI aHR 0,720 (0,588–0,881)
- Hospitalisierter Schlaganfall aHR 0,575 (0,533–0,619)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 09.08.2025. Verfasst von Emily Rayens und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: Myocardial Infarction, Herpes Zoster Vaccine, Herpes Zoster Ophthalmicus, Stroke. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Herpes zoster (HZ) and HZ ophthalmicus (HZO) are associated with an increased risk of cardiovascular complications, such as acute myocardial infarction (AMI) and stroke. We evaluated the association between recombinant zoster vaccine (RZV) and risk of HZO, hospitalized AMI, and hospitalized stroke in adults ≥50 years of age (YoA) at Kaiser Permanente Southern California.
Methods
We conducted a matched cohort analysis of adults ≥50 YoA who received 2 doses of RZV 4 weeks–6 months apart during 01 April 2018–31 December 2020 and were matched 1:4 to RZV-unvaccinated individuals on age, sex, race/ethnicity, and index date (date of second dose among vaccinated; unvaccinated match assigned same date). Follow-up started at index date and ended at receipt of zoster vaccine, termination of membership, death, or 31 December 2022, whichever came first. HZO was identified by natural language processing of clinical notes; hospitalized AMI and stroke were identified by ICD-10 codes. Stratified Cox proportional hazards regression was used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI).
Results
Among 102 766 2-dose RZV-vaccinated and 411 064 unvaccinated adults, 59.0% were female, 57.1% non-Hispanic White, and median age was 68 years (range: 50–108). The aHRs (95% CI) of HZO, hospitalized AMI, and hospitalized stroke comparing RZV-vaccinated and unvaccinated individuals were 0.271 (95% CI: 0.222, 0.330), 0.720 (0.588–0.881), and 0.575 (0.533–0.619), respectively. The adjusted RZV effectiveness against HZO was 72.9% (67.0%–77.8%).
Conclusions
Among adults ≥50 YoA, 2 RZV doses were associated with a lower risk of HZO, AMI, and stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
- Center for Integrated Health Care Research, Kaiser Permanente Hawaii, Honolulu, Hawaii, USA.
- GSK, Rockville, Maryland, USA.
- Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
ORCID-Profile: Emily Rayens, Lina S Sy, Lei Qian, Jun Wu, Bradley K Ackerson, Yi Luo, Chengyi Zheng, Yanjun Cheng, Leticia I Vega Daily, Jeannie Song, Harpreet S Takhar, Jennifer H Ku, Rachel A Cohen, Huifeng Yun, Driss Oraichi, Harry Seifert, Hung-Fu Tseng
Förderung
- GSK
Zitieren
APA
Rayens, E., Sy, L. S., Qian, L., Wu, J., Ackerson, B. K., Luo, Y., Zheng, C., Cheng, Y., Vega Daily, L. I., Song, J., Takhar, H. S., Ku, J. H., Cohen, R. A., Yun, H., Oraichi, D., Seifert, H., & Tseng, H. F. (2025). Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years. Clinical Infectious Diseases, 81(5), e441-e445. https://doi.org/10.1093/cid/ciaf440
Vancouver
Rayens E, Sy LS, Qian L, Wu J, Ackerson BK, Luo Y, et al. Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years. Clinical Infectious Diseases. 2025;81(5):e441-e445. doi:10.1093/cid/ciaf440
BibTeX
@article{Rayens2025,
author = {Rayens, Emily and Sy, Lina S and Qian, Lei and Wu, Jun and Ackerson, Bradley K and Luo, Yi and Zheng, Chengyi and Cheng, Yanjun and Vega Daily, Leticia I and Song, Jeannie and Takhar, Harpreet S and Ku, Jennifer H and Cohen, Rachel A and Yun, Huifeng and Oraichi, Driss and Seifert, Harry and Tseng, Hung-Fu},
title = {Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {5},
pages = {e441--e445},
doi = {10.1093/cid/ciaf440}
}
EUVIMED